345 related articles for article (PubMed ID: 27312361)
21. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial.
Fliser D; Dellanna F; Koch M; Wiggenhauser A;
Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540
[TBL] [Abstract][Full Text] [Related]
22. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
[TBL] [Abstract][Full Text] [Related]
23. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
24. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
25. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
26. Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis.
Vankar SG; Dutta P; Kohli HS; Bhansali A
Indian J Med Res; 2014 Jan; 139(1):112-6. PubMed ID: 24604046
[TBL] [Abstract][Full Text] [Related]
27. A single arm, prospective, open label, multicentre study for evaluation of efficacy and safety of IV CERA for treatment of chronic renal anaemia in dialysis patients not currently treated with ESA.
Nainan GK; Pathak VR; Dalal SS; Saxena S; Mittal D; Raju TR; Gokulnath ; Isaac R; Rajapurkar MM; Rana DS; Shah BV; Ray DS; Thiagarajan CM; Jha RM; Kukreja AA; Pophale RR
J Assoc Physicians India; 2014 Mar; 62(3):232-6. PubMed ID: 25327065
[TBL] [Abstract][Full Text] [Related]
28. Relationship between responsiveness to erythropoiesis-stimulating agent and long-term outcomes in chronic hemodialysis patients: a single-center cohort study.
Ogawa T; Shimizu H; Kyono A; Sato M; Yamashita T; Otsuka K; Nitta K
Int Urol Nephrol; 2014 Jan; 46(1):151-9. PubMed ID: 23807369
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
Kacarska-Fotevska II; Volckova N; Ilievska K; Donev D
Med Arch; 2020 Apr; 74(2):109-114. PubMed ID: 32577051
[TBL] [Abstract][Full Text] [Related]
30. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis.
Selby NM; Fonseca SA; Fluck RJ; Taal MW
Perit Dial Int; 2012; 32(2):177-82. PubMed ID: 22045101
[TBL] [Abstract][Full Text] [Related]
31. Correction of anemia with continuous erythropoietin receptor activator in Korean patients on long-term hemodialysis.
Oh J; Joo KW; Chin HJ; Chae DW; Kim SG; Kim SJ; Chung W; Kim S; Huh W; Oh HY; Choi BS; Yang CW; Kim S
J Korean Med Sci; 2014 Jan; 29(1):76-83. PubMed ID: 24431909
[TBL] [Abstract][Full Text] [Related]
32. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
[TBL] [Abstract][Full Text] [Related]
33. A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study.
Akizawa T; Tsubakihara Y; Hirakata H; Watanabe Y; Hase H; Nishi S; Babazono T; Kumagai M; Katakura S; Uemura Y; Ohashi Y;
Clin Exp Nephrol; 2016 Dec; 20(6):885-895. PubMed ID: 26779906
[TBL] [Abstract][Full Text] [Related]
34. Dosing regimen and tolerability of methoxy polyethylene glycol-epoetin beta in Chinese dialysis patients.
Choy BY; Lam MF; Yip T; Tang HL; Wong PN; Chow CC; Yap DY; Chan TM
Nephrology (Carlton); 2013 Aug; 18(8):533-8. PubMed ID: 23714233
[TBL] [Abstract][Full Text] [Related]
35. [Predictors of response to the CERA in chronic hemodialysis treatment-naive by erythropoiesis-stimulating agent].
Ezziani M; Najdi A; Mikou S; Hanin H; Arrayhani M; Houssaini TS
Pan Afr Med J; 2015; 20():331. PubMed ID: 26175821
[TBL] [Abstract][Full Text] [Related]
36. CERA: third-generation erythropoiesis-stimulating agent.
Topf JM
Expert Opin Pharmacother; 2008 Apr; 9(5):839-49. PubMed ID: 18345959
[TBL] [Abstract][Full Text] [Related]
37. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Inrig JK; Barnhart HX; Reddan D; Patel UD; Sapp S; Califf RM; Singh AK; Szczech LA
Am J Kidney Dis; 2012 Sep; 60(3):390-401. PubMed ID: 22537421
[TBL] [Abstract][Full Text] [Related]
38. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
39. Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.
Chacón-Araya M; Rey-Rodríguez D; Rodríguez De León F; Ramos-Esquivel A; Sunning T
J Med Econ; 2019 Aug; 22(8):736-741. PubMed ID: 30915883
[No Abstract] [Full Text] [Related]
40. Once-Monthly Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Hemodialysis-Dependent Chronic Kidney Disease: Pooled Data from Phase III Trials.
Locatelli F; Choukroun G; Truman M; Wiggenhauser A; Fliser D
Adv Ther; 2016 Apr; 33(4):610-25. PubMed ID: 26965694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
